The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Open accessAbstract
OBJECTIVES: A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on efficacy/safety. METHODS: Literature searches were conducted through November 2016 to identify controlled and observational studies of biologics/biosimilars administered for treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), psoriasis (Ps), Crohn's disease, and ulcerative colitis. RESULTS: Of >21,000 screened publications, 443 were included. Anti-drug antibody (ADAb) rates varied widely among biologics across diseases (and are not directly comparable because of immunoassay heterogeneity); the highest overall rates were reported with infliximab (0-83%), adalimumab (0-54%), and infliximab biosimilar CT-P13 (21-52%), and the lowest with secukinumab (0-1%), ustekinumab (1-11%), etanercept (0-13%), and golimumab (0-19%). Most ADAbs were neutralizing, except those to abatacept and etanercept. ADAb+ versus ADAb- patients had lower rates of clinical response to adalimumab (RA, PsA, JIA, AS, Ps), golimumab (RA), infliximab (RA, PsA, AS, Ps), rituximab (RA), ustekinumab (Ps), and CT-P13 (RA, AS). Higher rates of infusion-related reactions were reported in infliximab- and CT-P13-treated ADAb+ patients. Background immunosuppressives/anti-proliferatives reduced biologic immunogenicity across diseases. CONCLUSIONS: Based on reviewed reports, biologic/biosimilar immunogenicity differs among agents, with the highest rates observed with infliximab and adalimumab. As ADAb formation in biologic-/biosimilar-treated patients may increase the risk of lost response, the immunogenicity of these agents is an important (albeit not the only) consideration in the treatment decision-making process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Downs, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,540
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Sandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J.-F., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.05.048 · Cited by 940
Hyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J., Liu, G., Travers, S., Heuschkel, R., Markowitz, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.003 · Cited by 877
van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Sandborn, W. J., Feagan, B. G., Marano, C., Zhang, H., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Colombel, J., Reinisch, W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.06.010 · Cited by 727
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
Antoni, C., Krueger, G. G., de Vlam, K., Birbara, C., Beutler, A., Guzzo, C., Zhou, B., Dooley, L. T., & Kavanaugh, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032268 · Cited by 715
Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis
Lovell, D. J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K., Nemcova, D., Mouy, R., Sandborg, C., Bohnsack, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706290 · Cited by 625
Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., Mikazane, H., Gutierrez-Ureña, S., Lim, M., Lee, Y.-A., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203091 · Cited by 606
Vermeire, S., Noman, M., Van Assche, G., Baert, F., D’Haens, G., & Rutgeerts, P. (2007) · Gut · doi:10.1136/gut.2006.099978 · Cited by 602
Inman, R. D., Davis, J. C., Heijde, D. V. D., Diekman, L., Sieper, J., Kim, S. I., Mack, M., Han, J., Visvanathan, S., Xu, Z., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23969 · Cited by 593
Gottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550
Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Afif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.9 · Cited by 486
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
Steenholdt, C., Brynskov, J., Thomsen, O. Ø., Munck, L. K., Fallingborg, J., Christensen, L. A., Pedersen, G., Kjeldsen, J., Jacobsen, B. A., Oxholm, A. S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305279 · Cited by 460
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
van Schouwenburg, P. A., Rispens, T., & Wolbink, G. J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.4 · Cited by 438
Garcês, S., Demengeot, J., & Benito-Garcia, E. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202220 · Cited by 411
Ruperto, N., Lovell, D. J., Cuttica, R., Wilkinson, N., Woo, P., Espada, G., Wouters, C., Silverman, E. D., Balogh, Z., Henrickson, M., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22838 · Cited by 410
Emery, P., Fleischmann, R. M., Moreland, L. W., Hsia, E. C., Strusberg, I., Durez, P., Nash, P., Amante, E. J. B., Churchill, M., Park, W., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24638 · Cited by 398
Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22214 · Cited by 384
Radstake, T. R. D. J., Svenson, M., Eijsbouts, A. M., van den Hoogen, F. H. J., Enevold, C., van Riel, P. L. C. M., & Bendtzen, K. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092833 · Cited by 377
Vincent, F. B., Morand, E. F., Murphy, K., Mackay, F., Mariette, X., & Marcelli, C. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202545 · Cited by 356
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Vande Casteele, N., Gils, A., Singh, S., Ohrmund, L., Hauenstein, S., Rutgeerts, P., & Vermeire, S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.12 · Cited by 346
Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F., Borenstein, D., Box, J., Coteur, G., Goel, N., Brezinschek, H.-P., Innes, A., & Strand, V (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.099291 · Cited by 338
Self-citationFeagan, B. G., McDonald, J. W. D., Panaccione, R., Enns, R. A., Bernstein, C. N., Ponich, T. P., Bourdages, R., MacIntosh, D. G., Dallaire, C., Cohen, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.024 · Cited by 331
Yanai, H., Lichtenstein, L., Assa, A., Mazor, Y., Weiss, B., Levine, A., Ron, Y., Kopylov, U., Bujanover, Y., Rosenbach, Y., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.07.029 · Cited by 316
Ungar, B., Chowers, Y., Yavzori, M., Picard, O., Fudim, E., Har-Noy, O., Kopylov, U., Eliakim, R., Ben-Horin, S., & on behalf of ABIRISK consortium (2014) · Gut · doi:10.1136/gutjnl-2013-305259 · Cited by 309
Yoo, D. H., Prodanovic, N., Jaworski, J., Miranda, P., Ramiterre, E., Lanzon, A., Baranauskaite, A., Wiland, P., Abud-Mendoza, C., Oparanov, B., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208786 · Cited by 279
Pascual-Salcedo, D., Plasencia, C., Ramiro, S., Nuno, L., Bonilla, G., Nagore, D., Ruiz del Agua, A., Martinez, A., Aarden, L., Martin-Mola, E., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/ker124 · Cited by 256
Self-citationBurmester, G. R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., Rangaraj, M. J., Roane, G., Ludivico, C., Lu, P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203523 · Cited by 243
Krieckaert, C. L., Nurmohamed, M. T., & Wolbink, G. J. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201544 · Cited by 242
Bortlik, M., Duricova, D., Malickova, K., Machkova, N., Bouzkova, E., Hrdlicka, L., Komarek, A., & Lukas, M. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.10.019 · Cited by 232
Emery, P., Vencovský, J., Sylwestrzak, A., Leszczyński, P., Porawska, W., Baranauskaite, A., Tseluyko, V., Zhdan, V. M., Stasiuk, B., Milasiene, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207588 · Cited by 231
Paul, S., Del Tedesco, E., Marotte, H., Rinaudo-Gaujous, M., Moreau, A., Phelip, J.-M., Genin, C., Peyrin-Biroulet, L., & Roblin, X. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182a77b41 · Cited by 222
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
Jani, M., Barton, A., Warren, R. B., Griffiths, C. E. M., & Chinoy, H. (2014) · Rheumatology · doi:10.1093/rheumatology/ket260 · Cited by 217
Biologic therapies in rheumatology: lessons learned, future directions
Strand, V., Kimberly, R., & Isaacs, J. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2196 · Cited by 216
Self-citationImmunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
WEST, R. L., ZELINKOVA, Z., WOLBINK, G. J., KUIPERS, E. J., STOKKERS, P. C. F., & VAN DER WOUDE, C. J. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03828.x · Cited by 213
Tsai, T.-F., Ho, J.-C., Song, M., Szapary, P., Guzzo, C., Shen, Y.-K., Li, S., Kim, K.-J., Kim, T.-Y., Choi, J.-H., et al. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.05.005 · Cited by 212
van Schouwenburg, P. A., van de Stadt, L. A., de Jong, R. N., van Buren, E. E. L., Kruithof, S., de Groot, E., Hart, M., van Ham, S. M., Rispens, T., Aarden, L., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201445 · Cited by 203
Roblin, X., Rinaudo, M., Del Tedesco, E., Phelip, J. M., Genin, C., Peyrin-Biroulet, L., & Paul, S. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.146 · Cited by 195
Cohen, S., Genovese, M. C., Choy, E., Perez-Ruiz, F., Matsumoto, A., Pavelka, K., Pablos, J. L., Rizzo, W., Hrycaj, P., Zhang, N., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210459 · Cited by 185
ASAHINA, A., NAKAGAWA, H., ETOH, T., OHTSUKI, M., & THE ADALIMUMAB M04‐688 STUDY GROUP (2010) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2009.00748.x · Cited by 184
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
Sandborn, W. J., Schreiber, S., Feagan, B. G., Rutgeerts, P., Younes, Z. H., Bloomfield, R., Coteur, G., Guzman, J. P., & D'Haens, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.031 · Cited by 175
Ducourau, E., Mulleman, D., Paintaud, G., Miow Lin, D. C., Lauféron, F., Ternant, D., Watier, H., & Goupille, P. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3386 · Cited by 164
de Vries, M. K., Wolbink, G., Stapel, S. O., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.072397 · Cited by 154
Ruperto, N., Lovell, D. J., Cuttica, R. J., Woo, P. M., Meiorin, S., Wouters, C. H., Silverman, E. D., Balogh, Z. J., Henrickson, M., Davidson, J. E., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.100354 · Cited by 150
Lecluse, L. L. A., Driessen, R. J. B., Spuls, P. I., de Jong, E. M. G. J., Stapel, S. O., van Doorn, M. B. A., Bos, J. D., & Wolbink, G. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2009.347 · Cited by 148
Deodhar, A. A., Braun, J., Inman, R. D., van der Heijde, D. M. F. M., Zhou, Y., Xu, S., Han, C., & Hsu, B. L. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-205862 · Cited by 146
Miyasaka, N., & The CHANGE Study Investigators (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0045-0 · Cited by 144
Dougados, M., Kissel, K., Conaghan, P., Mola, E., Schett, G., Gerli, R., Hansen, M., Amital, H., Xavier, R., Troum, O., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204761 · Cited by 143
Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. Ø., & Ainsworth, M. A. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.106 · Cited by 136
van Schie, K. A., Hart, M. H. L., de Groot, E. R., Kruithof, S., Aarden, L. A., Wolbink, G., & Rispens, T. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206237 · Cited by 132
Allez, M. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95055-5 · Cited by 125
Miele, E., Markowitz, J. E., Mamula, P., & Baldassano, R. N. (2004) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200405000-00008 · Cited by 125
Kremer, J. M., Ritchlin, C. T., Mendelsohn, A. M., Baker, D., Kim, L., Xu, Z., Han, J. S., & Taylor, P. C. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27348 · Cited by 124
Plasencia, C., Pascual‐Salcedo, D., Nuño, L., Bonilla, G., Villalba, A., Peiteado, D., Díez, J., Nagore, D., del Agua, A. R., Moral, R. M. G. D., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200828 · Cited by 122
Self-citationKorswagen, L.-A., Bartelds, G. M., Krieckaert, C. L. M., Turkstra, F., Nurmohamed, M. T., van Schaardenburg, D., Wijbrandts, C. A., Tak, P. P., Lems, W. F., Dijkmans, B. A. C., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30209 · Cited by 121
Jani, M., Chinoy, H., Warren, R. B., Griffiths, C. E. M., Plant, D., Fu, B., Morgan, A. W., Wilson, A. G., Isaacs, J. D., Hyrich, K. L., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39169 · Cited by 117
Thurlings, R. M., Teng, O. Y., Vos, K., Gerlag, D. M., Aarden, L. A., Stapel, S. O., van Laar, J. M., Tak, P. P., & Wolbink, G. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109041 · Cited by 116
Yarur, A. J., Jain, A., Hauenstein, S. I., Quintero, M. A., Barkin, J. S., Deshpande, A. R., Sussman, D. A., Singh, S., & Abreu, M. T. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000689 · Cited by 116
Frederiksen, M. T., Ainsworth, M. A., Brynskov, J., Thomsen, O. Ø., Bendtzen, K., & Steenholdt, C. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000138 · Cited by 115
Chen, D.-Y., Chen, Y., Tsai, W., Tseng, J.-C., Chen, Y., Hsieh, C.-W., Hung, W., & Lan, J. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203893 · Cited by 115
Park, S. J., Cheon, E. J., Lee, M. H., & Kim, H. A. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38188 · Cited by 111
Lichtenstein, G. R., Thomsen, O. Ø., Schreiber, S., Lawrance, I. C., Hanauer, S. B., Bloomfield, R., & Sandborn, W. J. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.01.014 · Cited by 109
Steenholdt, C., Al-Khalaf, M. A. R., Brynskov, J., Bendtzen, K., Thomsen, O., & Ainsworth, M. A. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22910 · Cited by 108
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period
Braun, J., Deodhar, A. A., Dijkmans, B. A. C., Geusens, P., Sieper, J., Williamson, P., Xu, W., Visvanathan, S., Baker, D., Goldstein, N. H., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.24001 · Cited by 106
de Vries, M. K., Brouwer, E., van der Horst-Bruinsma, I. E., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109702 · Cited by 103
Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes
Jullien, D., Prinz, J. C., & Nestle, F. O. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.295 · Cited by 102
Levesque, B. G., Greenberg, G. R., Zou, G., Sandborn, W. J., Singh, S., Hauenstein, S. I., Ohrmund, L., Wong, C. J., Stitt, L., Shackelton, L. M., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12733 · Cited by 101
van Schouwenburg, P. A., Krieckaert, C. L. M., Rispens, T., Aarden, L. A., Wolbink, G., & Wouters, D. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202407 · Cited by 97
Baert, F., Kondragunta, V., Lockton, S., Casteele, N. V., Hauenstein, S. I., Singh, S., Κarmiris, K., Ferrante, M., Gils, A., & Vermeire, S. (2015) · Gut · doi:10.1136/gutjnl-2014-307882 · Cited by 94
Zhuang, Y., Xu, Z., Frederick, B., de Vries, D. E., Ford, J. A., Keen, M., Doyle, M. K., Petty, K. J., Davis, H. M., & Zhou, H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.015 · Cited by 94
Lovell, D. J., Ruperto, N., Mouy, R., Paz, E. G., Rubio‐Pérez, N., Silva, C. A., Abud‐Mendoza, C., Burgos‐Vargas, R., Gerloni, V., Melo‐Gomes, J. A., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39234 · Cited by 92
Kohno, T., Tam, L. T., Stevens, S. R., & Louie, J. S. (2007) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650034 · Cited by 91
Magdelaine–Beuzelin, C., Vermeire, S., Goodall, M. D., Baert, F., Noman, M., Assche, G. V., Ohresser, M. C. P., Degenne, D., Dugoujon, J., Jefferis, R., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a06bf · Cited by 88
Garcês, S., Antunes, M. C. D. S., Benito‐Garcia, E., da Silva, J. C., Aarden, L. A., & Demengeot, J. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203296 · Cited by 87
van der Bijl, A. E., Breedveld, F. C., Antoni, C., Kalden, J. R., Kary, S., Burmester, G. R., Beckmann, C., Unnebrink, K., & Küpper, H. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0866-4 · Cited by 82
Isozaki, T., Arbab, A. S., Haas, C. S., Amin, M. A., Arendt, M. D., Koch, A. E., & Ruth, J. H. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37981 · Cited by 80
Optimizing the use of biological therapy in patients with inflammatory bowel disease
Moss, A. C. (2015) · Gastroenterology report · doi:10.1093/gastro/gou087 · Cited by 76
Biologic Concentration Testing in Inflammatory Bowel Disease
Vaughn, B. P., Sandborn, W. J., & Cheifetz, A. S. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000312 · Cited by 73
Immunogenicity of biological therapeutics: from assay to patient
Krieckaert, C. L. M., Rispens, T., & Wolbink, G. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283521c4e · Cited by 73
Krintel, S. B., Grunert, V. P., Hetland, M. L., Johansen, J. S., Rothfuß, M., Palermo, G., Essioux, L., & Klause, U. (2013) · Rheumatology · doi:10.1093/rheumatology/ket017 · Cited by 71
Krieckaert, C. L. M., Jamnitski, A., Nurmohamed, M. T., Kostense, P. J., Boers, M., & Wolbink, G. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34680 · Cited by 67
van Schaik, T., Maljaars, J., Roopram, R. K., Verwey, M. H., Ipenburg, N., Hardwick, J. C. H., Veenendaal, R. A., & Jong, A. E. V. D. M. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000208 · Cited by 67
Takeuchi, T., Harigai, M., Tanaka, Y., Yamanaka, H., Ishiguro, N., Yamamoto, K., Miyasaka, N., Koike, T., Kanazawa, M., Oba, T., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201796 · Cited by 61
Self-citationImaeda, H., Andoh, A., & Fujiyama, Y. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0474-y · Cited by 54
Keystone, E. C., Kremer, J. M., RUSSELL, A. S., Box, J., Abud‐Mendoza, C., Garza‐Elizondo, M. A., Luo, A. Y., Aranda, R., Delaet, I., Swanink, R., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200355 · Cited by 53
Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide
Hendy, P., Hart, A. L., & Irving, P. M. (2015) · Frontline Gastroenterology · doi:10.1136/flgastro-2014-100527 · Cited by 49
Smolen, J. S., Kay, J., Doyle, M. K., Landewé, R., Matteson, E. L., GAYLIS, N. B., Wollenhaupt, J., Murphy, F. T., Xu, S., Zhou, Y., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0516-6 · Cited by 49
Mostafa, N. M., Nader, A. M., Noertersheuser, P. A., Okun, M. M., & Awni, W. M. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13884 · Cited by 48
van den Bemt, B. J. F., den Broeder, A. A., Wolbink, G., Hekster, Y. A., van Riel, P. L. C. M., Benraad, B., & van den Hoogen, F. H. J. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-12 · Cited by 42
Weinblatt, M. E., Westhovens, R., Mendelsohn, A. M., Kim, L., Lo, K. H., Sheng, S., Noonan, L., Lu, J., Xu, Z., Leu, J. H., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203742 · Cited by 40
Skrabl‐Baumgartner, A., Erwa, W., Muntean, W. E., et al. (2015) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2015.1022213 · Cited by 38
Christen, U., Thuerkauf, R., Stevens, R. M., & Lesslauer, W. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00068-3 · Cited by 34
Hayes, M., Stein, A. C., & Sakuraba, A. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12517 · Cited by 33
Hoxha, A., Calligaro, A., Tonello, M., Ramonda, R., Carletto, A., Paolazzi, G., Bortolotti, R., Ross, T. D., Grava, C., Boaretto, M., et al. (2015) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.04.020 · Cited by 29
Bingham, C. O., Mendelsohn, A. M., Kim, L., Xu, Z., Leu, J. H., Han, C., Lo, K. H., Westhovens, R., Weinblatt, M. E., & on behalf of the GO‐FURTHER Investigators (2015) · Arthritis Care & Research · doi:10.1002/acr.22556 · Cited by 19
Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
Ungar, B., Haj-Natour, O., Kopylov, U., Yavzori, M., Fudim, E., Picard, O., Loebstein, R., Lahat, A., Maor, Y., Avidan, B., et al. (2015) · Medicine · doi:10.1097/md.0000000000000673 · Cited by 18
Eng, G. P., Bendtzen, K., Bliddal, H., Stoltenberg, M., Szkudlarek, M., Fana, V., Lindegaard, H., Omerovic, E., Højgaard, P., Jensen, E. K., et al. (2015) · Arthritis · doi:10.1155/2015/784825 · Cited by 14
Amano, K., Matsubara, T., Tanaka, T., Inoue, H., Iwahashi, M., Kanamono, T., Nakano, T., Uchimura, S., Izumihara, T., Yamazaki, A., et al. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1012786 · Cited by 13
Self-citationIshikawa, Y., Fujii, T., Ishikawa, S., Yukawa, N., Hashimoto, M., Furu, M., Ito, H., Ohmura, K., & Mimori, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162896 · Cited by 11
Bessette, L., Khraishi, M. M., Kivitz, A., Kaliyaperumal, A., Grantab, R., Poulin-Costello, M., Isaila, M., & Collier, D. H. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0079-x · Cited by 11
Malíčková, K., Ďuricová, D., Bortlík, M., Janatková, I., Zima, T., & Lukáš, M. (2012) · Autoimmunity Highlights · doi:10.1007/s13317-012-0045-0 · Cited by 3
Monitoring of anti-TNF biological treatments
del Agua, A. R., Pascual‐Salcedo, D., Balsa, A., Ramos, I., Novalbos, L., Ramiro, S., Martínez, A. A. P., Simón, L., & Nagore, D. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-s1-p32 · Cited by 3
Self-citationAncuța, C., Pomîrleanu, C., Belibou, C., Maxim, R., Petrariu, L., Strugariu, G., & Chirieac, R. M. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.1886 · Cited by 2
Cited by
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis Care & Research · doi:10.1002/acr.24596 · Cited by 1,341
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41752 · Cited by 1,042
T cell subsets and functions in atherosclerosis
Saigusa, R., Winkels, H., & Ley, K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0352-5 · Cited by 721
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., Kataoka, Y., Chu, C.-Y., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 476
Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A. P., Winthrop, K. L., & Galloway, J. B. (2019) · Rheumatology · doi:10.1093/rheumatology/kez087 · Cited by 287
Metadata
- Authors
- Strand, V., Balsa, A., Al-Saleh, J., Barile-Fabris, L., Horiuchi, T., Takeuchi, T., Lula, S., Hawes, C., Kola, B., & Marshall, L.
- Venue
- BioDrugs
- Published
- 2017-06-13
- Volume
- 31
- Issue
- 4
- Pages
- 299-316
- ISSN
- 1172-7039 (ISSN-L)
- 1173-8804
- 1179-190X
- OpenAlex
- W2624671969
- Cited by
- 353
- References
- 122
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.